KR7006280002
KR7006280002
GC Biopharma Corp.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.48T EUR | 1.42T EUR | 1.69T EUR | 1.81T EUR |
Enterprise Value | 2.46T EUR | 2.31T EUR | 2.57T EUR | 2.75T EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -- | -- | -- | -- |
Price to Sales | 0.75x | 0.72x | 0.83x | 1.13x |
Price to Book | -- | 1.14x | 1.38x | 1.49x |
EV/Revenue | 1.25x | 1.18x | 1.26x | 1.71x |
EV/EBITDA | 18.52x | 13.63x | 11.75x | 18.51x |
Price to FCF (P/FCF) | 14.51x | 25.14x | 53.08x | 19.23x |
EV/FCF | 24.17x | 41.08x | 80.44x | 29.12x |
FCF Yield | 6.89% | 3.98% | 1.88% | 5.2% |